<DOC>
	<DOCNO>NCT01849003</DOCNO>
	<brief_summary>This mechanism action study evaluate effect oral GS-6615 QTc interval participant Long QT-3 syndrome . This study perform six cohort participant sequential manner , four single-dose cohort follow two multiple-dose cohort . Duration treatment single-dose cohort multiple-dose cohort 1 day 7 day , respectively . Participants confine study center check-in completion assessment discharge . Participants continuously monitor use real-time telemetry throughout in-clinic confinement . Physical examination include vital sign , laboratory analysis , electrocardiogram ( ECGs ) , Holter recording echocardiography ( ECHO ) perform defined time point throughout study period . Assessment adverse event concomitant medication continue throughout duration study .</brief_summary>
	<brief_title>Study Effect GS-6615 Subjects With LQT-3</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Long QT Syndrome</mesh_term>
	<criteria>1 . Males female age 1865 year ( inclusive ) time screen 2 . Documented LQT3 genotype one follow mutation : delta KPQ , R1623Q , N1325S , E1784K , S1787N , D1790G , G1631D , 1795insD , delF1617 , R1644H , L409P , F2004L , I1768V , T1304M , A1330T , F1596I3 . 3 . QTc &gt; 480 msec lead V5 screen 4 . Weight least 50 kg body mass index ( BMI ) 18 30 kg/m^2 ( inclusive ) 5 . Females childbearing potential must negative serum pregnancy test screen checkin 6 . Females childbearing potential must agree utilize protocol recommend highly effective contraception method three week prior single dose study drug 30 day follow single dose study drug . Females utilize hormonal contraceptive one birth control method must use method least 3 month prior study dose 7 . Males must agree utilize protocol recommend highly effective method contraception heterosexual intercourse throughout study period 90 day follow last dose study drug . Periodic abstinence withdrawal acceptable method contraception 8 . Males must refrain sperm donation Day 2 completion study continue least 90 day date last dose study drug 9 . Willing able comply requirement protocol direction clinic staff 10 . Willing avoid consumption grapefruit , grapefruit juice Seville oranges within 2 week prior single dose study drug discharge clinic 11 . Willing avoid consumption nicotine ( include nicotine gum ) alcoholic beverage within 2 week prior single dose study drug discharge clinic 12 . Understand willing sign inform consent 1 . Ongoing history medical surgical condition , judgment Investigator , might jeopardize individual 's safety interfere absorption , distribution , metabolism excretion study drug 2 . History meningitis encephalitis , seizure , migraine , tremor , myoclonic jerk , sleep disorder , anxiety , syncope , head injury family history seizures 3 . Any abnormal electrocardiographic ( ECG ) finding ( except QTc &gt; 460 msec ) screen judge clinically significant investigator 4 . Any abnormal laboratory value physical examination find screen checkin judge investigator clinically significant 5 . History positive serology test HIV , hepatitis B C 6 . Positive urine drug test ethanol , barbiturate , cocaine , opiates , amphetamine screen checkin 7 . Positive urine cotinine test checkin 8 . Current treatment drug affect QT interval 9 . Current treatment sodiumchannel blocker , eg , flecainide mexiletine 10 . Current treatment strong moderate inhibitor inducer cytochrome P450 ( CYP ) 3A4 1A2 11 . Prior treatment ranolazine within 7 day prior study drug administration 12 . Use systemic prescription medication overthecounter ( OTC ) medication , include multivitamin , dietary herbal supplement within 2 week 5 time terminal halflives medication ( whichever longer ) prior single dose study drug , duration study 13 . Use experimental investigational drug device within 30 day prior single dose study drug 5 halflives drug , whichever longer 14 . Females pregnant lactate 15 . History drug alcohol abuse within 12 month prior initial dose study drug 16 . Psychosocial addictive disorder would interfere ability give inform consent could compromise compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Long QT Syndrome</keyword>
	<keyword>LQTS</keyword>
	<keyword>Long QT-3 Syndrome</keyword>
	<keyword>LQT-3</keyword>
	<keyword>prolonged QT interval</keyword>
	<keyword>GS-6615</keyword>
	<keyword>late sodium current inhibitor</keyword>
</DOC>